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Abstract 
Background: Despite the availability of effective antidepressants, about half of patients with major depressive 
disorder (MDD) display an inadequate response to their initial treatment. A large patient survey recently reported that 
29.8% of MDD patients experiencing an inadequate treatment response felt frustrated about their medication and 
19.2% were frustrated with their healthcare provider. This survey and chart audit evaluated healthcare professionals’ 
(HCP) views on the emotional impact of having an inadequate response to antidepressant medication.
Methods: HCPs who frequently treat patients with MDD completed a survey and chart audit of their MDD patients 
currently experiencing an inadequate response to antidepressant treatment.
Results: 287 HCPs completed 1336 chart audits. HCPs reported that 38% of their patients were trusting/accepting 
of their MDD medications and 41% of their patients trusted/felt confident with their healthcare provision. Conversely, 
HCPs reported that 11% of their patients were frustrated with their medication and 5% with their healthcare benefits. 
HCPs cited impact on daily life (53%) and treatment issues (lack of efficacy and side effects; 50%) as the main drivers 
for their patients’ feelings of frustration. When HCPs recognized patients’ feelings of frustration, the top concerns of the 
HCPs were worsening of symptoms (43%) and non-compliance (41%).
Conclusions: This survey and chart audit highlights the emotional burden associated with inadequate responses 
to MDD treatment in addition to persistent symptoms. Differences between the views of the HCPs and patients are 
highlighted and suggest that HCPs may underestimate the full impact that having to try numerous medications has 
on their patients.
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Background
Despite the availability of many effective antidepres-
sants, in about half of patients, major depressive disorder 
(MDD) responds inadequately to the initial treatment, 
leaving patients to cope with persistent symptoms while 
their medication plan is optimized [1–3]. Persistence 
of depressive symptoms is known to be associated with 
various adverse outcomes, including a greater risk of 
relapse and recurrence [4, 5], a shorter duration between 
episodes [4], continued impairment in work and relation-
ships [6] and increased overall mortality from comorbid 
medical disorders [7–10].
We have recently reported the results of a large, inter-
national survey of 2096 patients with MDD which was 
designed to better understand the emotional impact 
of having an inadequate response to antidepressant 
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medication [11]. The patient survey found that the most 
frequently reported emotion associated with an inad-
equate treatment response was ‘frustration’ (29.8% of 
respondents). This frustration was directed towards their 
medication and/or their HCP, and was cited as a cause 
of patients wanting to stop their medication. To build 
an effective therapeutic alliance and help patients bet-
ter engage with their treatment plan, it is essential that 
HCPs understand the patient’s perspective. However, 
there is often a disconnect between the patient and HCP 
perceptions of depression management [12]. The aim of 
this HCP survey and chart audit was to evaluate HCP’s 
views on the emotional impact on the patient of having 
an inadequate response to antidepressant medication, 
and to compare these findings with the patient survey.
Methods
This HCP survey and chart audit was conducted in the 
United States (US), Canada, United Kingdom (UK), 
Germany, France, and Spain between 14 March and 15 
June 2016. No personal identifying information about 
any patient was requested and the audit was compli-
ant with the European Pharmaceutical Market Research 
Association (EphMRA) and Association of the British 
Pharmaceutical Industry (ABPI) Codes of Conduct and 
all guidelines set forth by the Health Insurance Port-
ability and Accountability Act (HIPAA). In line with the 
Data Protection Directive 95/46/EC, access to the online 
audit was secure and all relevant data was kept strictly 
confidential and anonymous. The authors designed the 
study and the survey and analyses were conducted by an 
independent market research agency (Market Strategies 
International, Livonia, MI, USA funded by Otsuka Phar-
maceutical Development & Commercialization, Inc. and 
H. Lundbeck A/S).
Participants
Respondents were recruited from a database of HCPs 
who have previously agreed to participate in research. 
HCP respondents had to be either a board certified/eli-
gible psychiatrist or a primary care physician (PCP; US 
only) with a 3–35-year history of practicing adult psy-
chiatry in the outpatient setting and currently spending 
at least 70% of time in direct patient care. All respond-
ents were required to be seeing at least 20 patients with 
MDD per month. HCPs working in mental health had to 
be currently initiating prescriptions for MDD (any treat-
ment) including atypical antipsychotics. Primary care 
physicians were required to be either initiating or refill-
ing prescriptions (any medication) for the treatment of 
MDD.
Study design
Respondents were blinded to the key study objectives, 
but were aware that the survey was designed to collect 
information on current MDD management with the aim 
of improving patient care. The study was carried out in 
two distinct parts. The first part was a survey about the 
HCP’s clinical practice, and for the second part, eligi-
ble respondents were asked to complete the chart audit 
for 5 outpatients with MDD who were still experiencing 
clinically significant depressive symptoms after at least 
6 weeks of antidepressant treatment at the recommended 
dose. It was estimated that it would take 45 min to com-
plete the audits over the course of a week (5–7 min per 
patient chart, preferably no more than one a day).
Chart audit
To ensure adequate recall, HCP respondents were 
instructed to complete each patient audit within 8  h of 
seeing the patient and were encouraged to refer to the 
patient medical record for accuracy. Full inclusion cri-
teria for suitable patients to be included in the audit are 
shown in Table 1.
The chart audit included up to 31 items (dependent on 
responses) and was structured to collect information on: 
patient characteristics, treatment history, clinical evalu-
ation, HCP perceptions of patient’s emotions associated 
with an inadequate response to treatment and the HCP 
respondent’s perception of whether their patients experi-
ence ‘frustration’ with aspects of their healthcare. As part 
of the patient characteristics section, HCP respondents 
were asked to rate their patient’s functional ability using 
the Sheehan Disability Scale (SDS) [13] where a score of 
0 represents no impact of symptoms on patient function 
and 10 represents ‘extreme’ disruption.
To assess how HCPs recognize patient feelings of 
frustration and dissatisfaction, respondents were first 
prompted to indicate how they believed their patients felt 
Table 1 Patient criteria for inclusion in audit
Age 18–65 years old
Diagnosed with major depressive disorder (MDD)
Has never had dysthymia
No other comorbid psychiatric conditions (e.g., schizoaffective disorder, 
etc.)
Being treated in an outpatient setting
Experiencing an MDD episode that required prescription treatment
Treated with an antidepressant at the recommended dose for at least 
6 weeks who still experiences clinically significant depressive symp-
toms
Has been taking prescription medication under your care for at least 
3 months for their current episode of MDD and whom you are seeing/
treating in a follow-up visit
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about their healthcare, choosing from a list of 14 multi-
choice answers. Feelings of frustration and dissatisfac-
tion were included as two of the 14 items. The 14 items 
were: understood, anonymous, frustrated, dissatisfied, 
neglected, confused, impatient/irritated, apprehensive, 
hopeless/doubtful, unimportant, ignored, trapped/help-
less, none of the above and I am not able to answer this 
question. If the HCP respondent identified feelings of 
either frustration or dissatisfaction in their patients, the 
next set of questions explored which aspects of health-
care they believed the patients were frustrated/dissatis-
fied with. Further questions included potential sources 
for frustration/dissatisfaction, and the impact of these 
feelings.
Data analysis
All HCP responses were coded and analyzed using 
descriptive statistics (means and frequency of responses).
Results
Sample
A total of 1300 HCPs were screened for inclusion in this 
survey. Of these, 287 met MDD practice criteria and 
agreed to the study requirements. Overall, 287 HCPs 
completed a total of 1336 patient chart audits, and of 
these 256 HCPs completed all 5 charts. Tables  2 and 3 
describe the HCP and patient characteristics, respec-
tively. Overall, 38% of patient charts were from the US, 
and the rest from the UK, France, Germany, Spain and 
Canada. Of the 513 US patient charts, half (n = 254 or 
19% of all charts) were completed by PCPs; all other 
patient charts were completed by psychiatrists.
Goal setting
Overall, HCPs reported discussing treatment goals with 
1189 (89%) of their patients. Of these, most (n = 1089; 
92%) said their patients agreed with the set goals and 
only 100 (8%) patients disagreed with the goals. From 
the HCP perspective, the main goals of treatment were 
‘improve symptoms of depression’ (54.8%), ‘improve 
social functioning’ (44%), ‘improve symptoms of anxiety’ 
(41%), ‘engage in social activities’ (39%), ‘reach remission 
and eventually be treatment free’ (30%), ‘improve sleep 
problems’ (30%), ‘improve cognitive symptoms’ (28%), ‘be 
able to be productive at work’ (27%) and ‘be able to better 
manage home duties’ (23%).
Emotions associated with an inadequate response 
to treatment
Per HCP report, a majority of patients were trusting/
accepting (38%) of their medications for MDD and a sim-
ilar proportion trusted/felt confident (41%) about their 
healthcare provider. Conversely, HCPs reported that 
about one in ten of their patients were frustrated (11%) 
and/or dissatisfied (9%) with their medication and one in 
twenty patients were frustrated (5%) and/or dissatisfied 
with the healthcare provider (Fig. 1).
Further analysis revealed that feelings of frustration and 
dissatisfaction with medication were identified signifi-
cantly more frequently by HCPs in patients with a longer 
history of MDD or who had more antidepressant fail-
ures. For example, HCPs identified frustration in 10.7% 
of patients with a 10-year history of depression (n = 22 of 
205 patients) compared to 4.5% in patients with a 2-year 
history (n = 6 of 134 patients). Likewise, HCPs identified 
feelings of frustration with medication in 7.3% of patients 
who had experienced 3 or more antidepressant treatment 
failures in the current episode (n = 48 of 660 patients) 
versus 1.8% in patients who had experienced two treat-
ment failures (n = 7 of 385 patients) and 2.7% in patients 
with one treatment failure (n = 8 of 291 patients). HCPs 
were also more likely to identify that their patients were 
frustrated with healthcare in patients who they had 
classed (using the SDS scale) as having severe disruption 
to their daily life (frustration with healthcare was identi-
fied in 3.8% of severely affected patients vs. 1.5% of mildly 
affected patients). Of note, HCPs practicing in Spain and 
France reported that fewer of their patients were frus-
trated with medication and/or healthcare (6 and 8%, 
Table 2 Characteristics of the HCP respondents
Variable N = 287
HCP specialty; n (%)
 Psychiatrist 234 (82%)
 US PCP 44 (15%)
 Internist/internal medicine 7 (2%)
 Nurse practitioner 2 (1%)
Mean years in practice [range] 17.0 years [3–35 years]
Mean percent of time spent in direct patient care 92%
Median estimated numbers of patients seen per month
 MDD 70
 Bipolar disorders 30
 Schizophrenia 30
 Schizoaffective disorder 15
HCP location; n (%)
 US 108 (38%)
 Canada 36 (13%)
 UK 40 (14%)
 Germany 35 (12%)
 France 37 (13%)
 Spain 31 (11%)
Setting
 Outpatient 251 (88%)
 Inpatient 36 (13%)
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respectively) compared with the USA (15%), Germany 
(12%), UK (17%) and Canada (17%).
Drivers and consequences of frustration in MDD
When the HCP identified that their patients had feelings 
of frustration or dissatisfaction with healthcare (n = 156 
patients), the main drivers of frustration were thought to 
be: impact on daily life (53%) and treatment issues (i.e., 
lack of efficacy and side effects; 50%). HCPs considered 
the medication regimen and having to change treatments 
as less important (both were considered a driver in 19% 
of patients) (Fig.  2a). HCPs identified that a wide range 
of symptoms may be related to frustration with health-
care, the most common being ‘feeling down, depressed 
or hopeless’ (38%) and feeling tired or having little energy 
(28%) (Fig. 2b).
In those patients recognized to be frustrated with their 
medication (n = 149), HCPs indicated that they are most 
likely to react by asking for a new prescription (37%), to 
make a new appointment (25%) and/or missing school 
(23%) (Fig. 3a). Likewise, in those patients believed to be 
frustrated with overall healthcare (n = 156), HCPs indi-
cated that they were more likely to ask for a new pre-
scription, but also to miss school or work and ask to see 
the doctor more frequently (Fig. 3b).
When HCPs recognized feelings of frustration in their 
patient, the top concerns were: worsening of symptoms 
(43%) and non-compliance (41%) (Fig.  4a). HCPs most 
commonly suggested non-pharmacological therapies 
(e.g., cognitive behavioral therapy), adjustment of medi-
cation doses, and/or lifestyle changes (Fig. 4b).
Discussion
To the best of our knowledge, this survey is the first to 
evaluate how HCPs perceive the emotional impact of 
inadequate response to antidepressant treatment on their 
patients. Although HCPs reported that a large percentage 
Table 3 Patient characteristics per chart audit
Variable Statistic
N = 1336
Setting
 Office 802 (60%)
 (US only) Outpatient Community Health Clinic 75 (6%)
 (France only) Centre Medical Psychologique 53 (4%)
 Hospital Outpatient Clinic 351 (26%)
 Telemedicine 12 (1%)
 Patient’s Home 23 (2%)
 Day Clinic 19 (1%)
 Other 1 (< 1%)
Length of MDD diagnosis
 < 1 month 88 (7%)
 1–3 months 174 (13%)
 4–6 months 180 (14%)
 7–9 months 65 (5%)
 10–12 months 211 (16%)
 2–5 years 370 (28%)
 6 + years 248 (19%)
Current treatment
 SSRI 800 (60%)
 SNRI 320 (24%)
 MAOI 7 (< 1%)
 TCA 49 (4%)
 Other antidepressant 295 (22%)
 Anxiolytic 239 (18%)
 Antipsychotic 243 (18%)
 Hypnotic 76 (6%)
 Other treatment for depression 69 (5%)
Mean current ADT duration by treatment class (weeks)
 SSRI 45.4
 SNRI 48.7
 MAOI 22.0
 TCA 106.8
 Other antidepressant 38.9
Number of current classes of prescription treatments for depression 
(this episode); n (%)
 0 6 (< 1%)
 1 755 (57%)
 2 397 (30%)
 3 145 (11%)
 4 28 (2%)
 5 + 5 (< 1%)
 Mean number 1.6
Level of functioning (mean SDS scores)
 SDS Mean score 5.1
 Work domain 6.0
 Social domain 4.7
 Home domain 4.5
PHQ-9 score (mean) 6.2
Table 3 (continued)
Variable Statistic
N = 1336
Clinical global impression of change in depression since onset of 
episode to current visit
 Very much worse 5 (< 1%)
 Much worse 63 (5%)
 Minimally worse 113 (9%)
 No change 248 (19%)
 Minimally improved 413 (31%)
 Much improved 400 (30%)
 Very much improved 94 (7%)
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of their patients experiencing inadequate response to 
antidepressant treatment had positive feelings about 
their medication and healthcare, they also identified a 
range of negative emotions including frustration and dis-
satisfaction, both with medications and overall health-
care. Such emotions are important to address, as they 
can directly impact medication adherence. Indeed, non-
compliance was one of the top concerns HCPs associated 
with patient frustration.
The results of this survey indicate that HCPs are aware 
of the wide range of negative emotions that can poten-
tially be associated with treatment failure and persistent 
depressive symptoms. No HCP reported that all of their 
patients included in the audit had only positive feelings 
towards their medication and/or healthcare. However, 
comparing the results of this survey to a recent patient 
survey, it appears that HCPs may significantly underesti-
mate how many of their own patients have negative emo-
tions towards their medication or healthcare, and may 
not be identifying the full impact of treatment failures on 
the patient experience. Whereas HCPs identified feelings 
of frustration with medication in 11% of their patients, 
the self-reported level of frustration in the patient sur-
vey was nearly three times higher (30%). Only half of the 
HCP respondents recognized frustration in any of their 
patients. Likewise, whereas HCPs recognized that 12% 
of their patients are frustrated with their healthcare, the 
patient survey indicated that a much larger percentage 
(27%) are frustrated with their overall healthcare, includ-
ing access to services and medications and experiences 
with their doctors, nurses and therapists.
Of note, HCPs only considered that 5% their patients 
are frustrated with their therapeutic relationship 
compared to 19% of patients in the patient survey. 
When HCPs did recognize feelings of frustration in their 
patients, they appeared to be aware of the potential 
impact of frustration on medication adherence and cited 
worsening of symptoms and non-adherence as their top 
concerns associated with frustration. However, it is nota-
ble that only 24% of HCPs identified patient frustration 
in the audit, and these HCPs usually identified it in 2 or 
3 of their 5 patient charts. The lack of recognition from 
the 76% of HCPs likely accounts for the discrepancy 
between the HCP and patient surveys in the reported 
prevalence of frustration in this patient population. Rec-
ognizing frustration with the therapeutic alliance is vital 
to address, because 29% of patients in the patient survey 
reported that they share less information when they are 
frustrated with their HCP and 27% reported wanting to 
quit their medication altogether. This insight is supported 
by the findings of another study based on in-depth inter-
views which found that MDD patients who had stopped 
taking their antidepressants had often experienced unsat-
isfactory interactions with HCPs [14]. Other qualitative 
studies have identified patient ambiguity and frustration 
with their medication (including time-frame of treat-
ment, efficacy and tolerability) as key reasons for medica-
tion non-adherence [15].
One practical way to improve the therapeutic alliance 
is to engage the patient in goal setting, so that they have 
reasonable expectations of their treatment. Moreover, it 
has been suggested that when patients receive treatment 
that they perceive as relevant to their individual needs, 
they are likely to exhibit greater commitment to their 
treatment regimen [16–18]. This, in turn, may help to sig-
nificantly decrease discontinuation of treatment, increase 
Fig. 1 HCP perceptions of how patients with MDD and experiencing treatment failures feel about a medications, b their healthcare provider
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satisfaction, and ultimately improve outcomes. In this 
survey, HCPs reported that they had discussed treatment 
goals with 90% of their patients. But in the patient sur-
vey, the proportion of patients who said treatment goals 
had been discussed with their HCPs was smaller (72%). 
Effective goal setting requires effective communication 
between the HCP and patient and it is a therapeutic skill 
that needs to be learned and practiced [19]. It may also be 
that some patients in the patient survey did not explicitly 
realize or remember that their HCP had discussed the 
Fig. 2 HCP perceived reasons for patient frustration with overall healthcare a overall, b current symptoms
Fig. 3 HCP perceived consequences of patient frustration with a medication, b overall healthcare
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goals of treatment. Interestingly, while patients and HCPs 
both agreed that their top goal for MDD treatment was 
to address depressive symptoms (55% in the HCP survey 
and 78% in the patient survey), patients are more inclined 
to expect improvement in anxiety (61% in patient survey 
vs. 41% in HCP survey) and sleep issues (51% in patient 
survey vs. 30% in HCP survey) than HCPs.
Strengths of the study include its international design 
and the timing of the patient audit where respondents 
were asked to record the data soon after they had seen 
the patient (limiting recall bias). Limitations of the sur-
vey include all those inherent to survey methodology 
including the process of recruitment which was limited 
to a commercial database of HCPs. Although there was 
consistency of most results across countries, this survey 
indicated that there may be some national differences 
in the perception of frustration, with lower levels being 
reported in Germany and France. This may be because of 
cultural differences in the patient population and/or in 
the healthcare system organization for MDD; and indeed, 
the patient survey found lower levels of patients express-
ing frustration in France [11]. Studies at the national level 
may be better able to tease out what aspects of care lead 
to frustration in each population. In addition, since the 
patient and HCP surveys were conducted separately, and 
patients were not matched to the HCP, a limitation of the 
various comparisons discussed above is that we cannot 
rule out the possibility that there were inherent differ-
ences in the patient populations surveyed. Although both 
surveys were conducted in the same countries, the sam-
ple size of the HCP survey was smaller than the patient 
survey (n = 287 HCP/1336 patient charts vs. n = 2096 
patients, respectively), and the relative representation of 
respondents from each country differed slightly (e.g., 38% 
of HCP respondents vs. 28.5% patient respondents were 
from the US). Moreover, it may be that patients experi-
encing frustration with their healthcare or medication 
are more likely to participate in a survey as a means to 
voice their dissatisfaction.
Conclusions
This survey highlights the high prevalence of wide-rang-
ing emotional burden associated with treatment failures 
in MDD. Although HCPs appear to be aware of some of 
the problems, the discrepancies between the results of 
this HCP survey and the patient survey [11] suggest that 
HCPs may often underestimate the full impact of having 
to try numerous medications has on their patients. The 
results can be considered a ‘call to action’ for clinicians 
to consider their management approach for patients who 
show an inadequate response to antidepressant treat-
ment. In particular, HCP awareness of how patients 
experience ‘frustration’ appears to be low compared to 
the self-reported prevalence in patients with MDD. This 
is important to consider because patients report that 
feelings of frustration may lead to poor adherence to 
medication, which will then continue to contribute to 
poor outcomes in patients.
Fig. 4 Impact of frustration a concerns about impact on the patient, b impact on treatment decisions
Page 8 of 8Mago et al. Ann Gen Psychiatry  (2018) 17:20 
Abbreviations
ABPI: Association of the British Pharmaceutical Industry; EphMRA: European 
Pharmaceutical Market Research Association; HCP: healthcare professional; 
HIPAA: Health Insurance Portability and Accountability Act; MDD: major 
depressive disorder; PCP: primary care physician.
Authors’ contributions
All authors conceptualized the survey and contributed to the interpretation of 
results and to the final version of the article. EW and CW wrote the first draft of 
the paper with direction from RM and AF. All authors read and approved the 
final manuscript.
Author details
1 Simple and Practical Mental Health, Philadelphia, PA, USA. 2 University 
of Siena Medical Center, Siena, Italy. 3 H. Lundbeck A/S, Valby, Denmark. 
4 Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, 
NJ, USA. 5 210 W Rittenhouse Square Suite 404, Philadelphia, PA 19103, USA. 
Acknowledgements
We wish to thank Katy Palmer (Market Strategies International) for help in 
conducting the study and analyses and Anita Chadha-Patel (ACP Clinical 
Communications Ltd, funded by Otsuka and H.Lundbeck A/S) for support 
in the preparation, revisions and editing of this paper. We also thank all the 
participant HCPs for taking the time to complete the surveys.
Competing interests
RM reports that in the previous 12 months, he received research grants 
from Alkermes, Allergan, Genomind, Takeda. He has been a consultant for 
GuidePoint Global, Lundbeck, Neurocrine, and Otsuka. He has developed and 
delivered educational activities for PsychU, funded by Otsuka Pharmaceuticals. 
He receives book royalties from On Demand Publishing and Kindle Direct 
Publishing. AF reports that he is/has been a consultant and/or a speaker and/
or has received research grants from Allergen, Angelini, Astra Zeneca, Bristol-
Myers Squibb, Boehringer Ingelheim, Pfizer, Eli Lilly, Ferrer, Janssen, Lundbeck, 
Novartis, Otsuka, and Roche. EW was employed by H.Lundbeck A/S at the 
time of the study and CW is employed by Otsuka.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Respondents were recruited from a database of HCPs who have previously 
agreed to participate in market research. The study was conducted in compli-
ance with relevant codes of conduct from the European Pharmaceutical 
Market Research Association and the Insights Association (formerly known 
as CASRO) in regards to PII and protective rights. Further, as noted in the 
exemption criteria outlined by The Department of Health and Human Services 
(see https ://www.hhs.gov/ohrp/regul ation s-and-polic y/regul ation s/45-cfr-46/
index .html#46.101(b)), this market research study does not require Clinical 
Research Ethics Committee or Independent Review Board approval.
Funding
This work has been sponsored by Otsuka Pharmaceutical Development & 
Commercialization, Inc. and H.Lundbeck A/S.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 2 March 2018   Accepted: 3 May 2018
References
 1. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase 
ME, Ritz L, Biggs MM, Warden D, Luther JF, et al. Bupropion-SR, sertraline, 
or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 
2006;354(12):1231–42.
 2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden 
D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and 
longer-term outcomes in depressed outpatients requiring one or several 
treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.
 3. Papakostas GI. Managing partial response or nonresponse: switching, 
augmentation, and combination strategies for major depressive disorder. 
J Clin Psychiatry. 2009;70(Suppl 6):16–25.
 4. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, 
Mueller T, Solomon DA, Keller MB. Does incomplete recovery from first 
lifetime major depressive episode herald a chronic course of illness? Am J 
Psychiatry. 2000;157(9):1501–4.
 5. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual 
symptoms after partial remission: an important outcome in depression. 
Psychol Med. 1995;25(6):1171–80.
 6. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markow-
itz JC, Schlager DS, Kornstein SG, Davis SM, et al. The treatment of chronic 
depression, part 3: psychosocial functioning before and after treatment 
with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608–19.
 7. Chang WH, Lee IH, Chen WT, Chen PS, Yang YK, Chen KC. Coexisting geri-
atric anxiety and depressive disorders may increase the risk of ischemic 
heart disease mortality—a nationwide longitudinal cohort study. Int J 
Geriatr Psychiatry. 2017;32(12):e25–33.
 8. Ho C, Jin A, Nyunt MS, Feng L, Ng TP. Mortality rates in major and sub-
threshold depression: 10-year follow-up of a Singaporean population 
cohort of older adults. Postgrad Med. 2016;128(7):642–7.
 9. Laforest L, Roche N, Devouassoux G, Belhassen M, Chouaid C, Ginoux 
M, Van Ganse E. Frequency of comorbidities in chronic obstructive pul-
monary disease, and impact on all-cause mortality: a population-based 
cohort study. Respir Med. 2016;117:33–9.
 10. Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. 
Mortality and life expectancy in persons with severe unipolar depression. 
J Affect Disord. 2016;193:203–7.
 11. Mago R, Fagiolini A, Weiller E, Weiss C. Understanding the emotions of 
patients with inadequate response to antidepressant treatments: results 
of an international online survey in patients with major depressive disor-
der. BMC Psychiatry. 2018;18(1):33.
 12. Lewis L, Hoofnagle L. Patient perspectives on provider competence: a 
view from the depression and bipolar support alliance. Adm Policy Ment 
Health. 2005;32(5–6):497–503.
 13. Sheehan DV. The Anxiety Disease. New York: Scribner’s; 1983.
 14. Anderson C, Roy T. Patient experiences of taking antidepressants for 
depression: a secondary qualitative analysis. Res Social Adm Pharm. 
2013;9(6):884–902.
 15. Buus N, Johannessen H, Stage KB. Explanatory models of depression 
and treatment adherence to antidepressant medication: a qualitative 
interview study. Int J Nurs Stud. 2012;49(10):1220–9.
 16. Battle CL, Uebelacker L, Friedman MA, Cardemil EV, Beevers CG, Miller IW. 
Treatment goals of depressed outpatients: a qualitative investigation of 
goals identified by participants in a depression treatment trial. J Psychiatr 
Pract. 2010;16(6):425–30.
 17. Dwight-Johnson M, Sherbourne CD, Liao D, Wells KB. Treatment prefer-
ences among depressed primary care patients. J Gen Intern Med. 
2000;15(8):527–34.
 18. Ruggeri M, Salvi G, Bonetto C, Lasalvia A, Allevi L, Parabiaghi A, Bertani M, 
Tansella M. Outcome of patients dropping out from community-based 
mental health care: a 6-year multiwave follow-up study. Acta Psychiatr 
Scand. 2007;437:42–52.
 19. Locke EA, Latham GP. Building a practically useful theory of goal setting 
and task motivation: a 35-year Odyssey. Am Psychol. 2002;57(9):705–17.
